The week in health tech, explained in plain English.Get the free newsletter →
October 28, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Health IT

Anthropic Buys Drug Startup, Reports Claude Results With 6 Partners

By Healthcare Technology News ·

Anthropic is pushing deeper into biotech. The AI company has acquired Mithril Medicine, a one-person startup developing treatments for two rare forms of muscular dystrophy, according to Becker's Hospital Review. The deal signals that Anthropic wants to do more than license its Claude models to drugmakers. It wants a stake in the science itself.

Alongside the acquisition, Anthropic on Oct. 27 released early results from Claude-assisted drug development work with six outside organizations: BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and the Column Group. The roster mixes large pharma, AI-native biotechs and investors, a sign that interest in applying frontier models to discovery spans the industry.

The move puts Anthropic in more direct competition with rivals like OpenAI and Google DeepMind, whose AlphaFold work reshaped protein science. For healthcare leaders, the takeaway is that AI vendors are no longer just tool suppliers. They are becoming participants in drug research, raising fresh questions about data, ownership and who ultimately controls the pipeline.

Sources

More in Health IT

Health IT

Does Long-Term AI Chatbot Use Cause Isolation? No One Knows

Researchers warn that long-term AI chatbot use may quietly drive social isolation, but a lack of access to usage data from AI companies makes the effect impossible to measure.

Why it matters: Hundreds of millions of people now use AI chatbots daily, yet the long-term mental health consequences remain unmeasured because the data sits locked inside private companies.

Health IT

How AI Aims to Give Physicians Their Attention Back

Health systems are deploying AI documentation and chart-summary tools to cut clerical work and let physicians focus on patients rather than screens.

Why it matters: Clerical burden is a leading driver of physician burnout, and AI that restores face-to-face attention could improve both clinician retention and patient trust.

Health IT

Moderna-Merck mRNA Cancer Vaccine Takes Center Stage at ESMO

Moderna and Merck's personalized mRNA cancer vaccine plus Keytruda headlined a marquee presentation at ESMO 2026 in Madrid, with Amgen's Imdelltra also in focus.

Why it matters: Proof that mRNA can power personalized cancer therapy would reshape oncology pipelines and investment across the industry.